{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:47:36Z","timestamp":1648907256699},"reference-count":52,"publisher":"Japanese Association of Virology","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Uirusu"],"published-print":{"date-parts":[[2005]]},"DOI":"10.2222\/jsv.55.85","type":"journal-article","created":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T06:00:56Z","timestamp":1132639256000},"page":"85-94","source":"Crossref","is-referenced-by-count":0,"title":["Progress in antiretroviral drugs"],"prefix":"10.2222","volume":"55","author":[{"given":"Wataru","family":"SUGIURA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1062","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mitsuya, H., K. J. Weinhold, P. A. Furman, M. H. St. Clair, S. N. Lehrman, R. C. Gallo, D. Bolognesi, D. W. Barry, and S. Broder. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 82: 7096-100, 1985.","DOI":"10.1073\/pnas.82.20.7096"},{"issue":"4953","key":"2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1126\/science.2183354","volume":"248","year":"1990","ISSN":"http:\/\/id.crossref.org\/issn\/0036-8075","issn-type":"print"},{"key":"3","unstructured":"3) CDC. 1999. HIV\/AIDS Surveillance Report."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mitsuya, H., and B. Samuel. Inhibition of the in vivo infectivity and cytopathic effect of human T-lymphotrophic virus type III\/lymphadenopathy-associated virus(HTLV-III\/LAV) by 2', 3'dideoxynucleosides. Proc Natl Acad Sci U S A 83: 1911-1915, 1986.","DOI":"10.1073\/pnas.83.6.1911"},{"issue":"1","key":"5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0006-291X(87)90460-8","volume":"142","year":"1987","ISSN":"http:\/\/id.crossref.org\/issn\/0006-291X","issn-type":"print"},{"issue":"7","key":"6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1128\/AAC.35.7.1386","volume":"35","year":"1991","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"5","key":"7","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1128\/AAC.41.5.1082","volume":"41","year":"1997","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Balzarini, J., L. Naesens, P. Herdewijn, I. Rosenberg, A. Holy, R. Pauwels, M. Baba, D. G. Johns, and E. De Clercq. Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A 86: 332-6, 1989.","DOI":"10.1073\/pnas.86.1.332"},{"issue":"2","key":"9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/AAC.37.2.332","volume":"37","year":"1993","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Lin, J. C., E. DeClercq, J. S. Pagano, Y. M. Mul, R. T. van Miltenburg, E. De Clercq, P. C. van der Vliet, M. S. Smith, and E. L. Brian. Novel acyclic adenosine analogs inhibit Epstein-Barr virus replication. Antimicrob Agents Chemother 31: 1431-3, 1987.","DOI":"10.1128\/AAC.31.9.1431"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Clercq, E. D. Potential of acyclic nucleoside phosphonates ij the treatment of DNA virus and retrovirus infections. Expert Rev. Anti-infect. Ther. 1: 21-42, 2003.","DOI":"10.1586\/14787210.1.1.21"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother 46: 1329-35, 2002.","DOI":"10.1128\/AAC.46.5.1329-1335.2002"},{"issue":"4","key":"13","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/AAC.43.4.802","volume":"43","author":"VAN ROMPAY K K A","year":"1999","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"11","key":"14","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1128\/AAC.40.11.2586","volume":"40","year":"1996","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"3","key":"15","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/AAC.42.3.612","volume":"42","year":"1998","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"7","key":"16","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/AAC.42.7.1568","volume":"42","year":"1998","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"6","key":"17","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1128\/AAC.42.6.1484","volume":"42","year":"1998","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"key":"18","unstructured":"18) Balzarini, J., and E. De Clercq. Nucleoside and Nucleotid Reverse Transcriptase Inhibitors. In E. De Clercq (ed.), Antiretroviral therapy. ASM press, Washington DC. 2001."},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(91)90063-W"},{"issue":"4","key":"20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1073\/pnas.88.4.1499","volume":"88","year":"1991","ISSN":"http:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Naeger, L. K., N. A. Margot, and M. D. Miller. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 46: 2179-84, 2002.","DOI":"10.1128\/AAC.46.7.2179-2184.2002"},{"key":"22","unstructured":"22) Parikh, U., D. Barnas, C. Bixby, H. Faruki, and J. W. Mellors. Presented at the 12th Conference on Retroviruses and Oppotunistic Infections, Boston MA. 2005."},{"issue":"4986","key":"23","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1126\/science.1701568","volume":"250","year":"1990","ISSN":"http:\/\/id.crossref.org\/issn\/0036-8075","issn-type":"print"},{"issue":"5","key":"24","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1128\/AAC.37.5.1127","volume":"37","year":"1993","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"issue":"12","key":"25","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1128\/AAC.39.12.2602","volume":"39","year":"1995","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2: 303-8, 1995.","DOI":"10.1038\/nsb0495-303"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1038\/nsb0595-407"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Motakis, D., and M. A. Parniak. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46: 1851-6, 2002.","DOI":"10.1128\/AAC.46.6.1851-1856.2002"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Van Herrewege, Y., J. Michiels, J. Van Roey, K. Fransen, L. Kestens, J. Balzarini, P. Lewi, G. Vanham, and P. Janssen. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother 48: 337-9, 2004.","DOI":"10.1128\/AAC.48.1.337-339.2004"},{"issue":"7","key":"30","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","volume":"92","year":"1995","ISSN":"http:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1021\/jm00047a001"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1021\/jm9704098"},{"issue":"12","key":"33","doi-asserted-by":"crossref","first-page":"3218","DOI":"10.1128\/AAC.42.12.3218","volume":"42","author":"SHAM H L","year":"1998","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2093-2099.2000"},{"key":"35","unstructured":"35) Redshaw, S., and G. J. Thomas. Inhibitor of protease, p. 151-180. In R. Unger, J. Kreuter, and H. Rubsamen-Waigmann (ed.), Antivirals Against AIDS. Marcel Dekker, Inc., NY. 2000."},{"issue":"24","key":"36","doi-asserted-by":"crossref","first-page":"14675","DOI":"10.1016\/S0021-9258(18)77355-9","volume":"265","year":"1990","ISSN":"http:\/\/id.crossref.org\/issn\/0021-9258","issn-type":"print"},{"key":"37","unstructured":"37) Kempf, D. J. Proetase Inhibitorr as anti-human immunodeficiency virus agents. In E. De Clercq (ed.), Antiretroviral Therapy. ASM press, Washington DC. 2001."},{"issue":"10","key":"38","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1128\/AAC.42.10.2637","volume":"42","author":"PATICK A K","year":"1998","ISSN":"http:\/\/id.crossref.org\/issn\/0066-4804","issn-type":"print"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Furfine, E. S., C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, A. Spaltenstein, R. Wood, K. Arasteh, H. J. Stellbrink, E. Teofilo, F. Raffi, R. B. Pollard, J. Eron, J. Yeo, J. Millard, M. B. Wire, and O. J. Naderer. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother 48: 791-8, 2004.","DOI":"10.1128\/AAC.48.3.791-798.2004"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.16.7462-7469.2001"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1324-1333.2003"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Colonno, R., R. Rose, C. McLaren, A. Thiry, N. Parkin, and J. Friborg. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 189: 1802-10, 2004.","DOI":"10.1086\/386291"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.5.2186"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Cervia, J. S., and M. A. Smith. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis 37: 1102-6, 2003.","DOI":"10.1086\/378302"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.092056199"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1126\/science.287.5453.646"},{"key":"47","unstructured":"47) Yoshinaga, T., A. Sato, T. Fujishita, and T. Fujiwara. Presented at the 9th Conference on Retroviruses and Oppotunistic Infections, Seattle WA. 2002."},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0402357101"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Pannecouque, C., W. Pluymers, B. Van Maele, V. Tetz, P. Cherepanov, E. De Clercq, M. Witvrouw, and Z. Debyser. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol 12: 1169-77, 2002.","DOI":"10.1016\/S0960-9822(02)00952-1"},{"key":"50","unstructured":"50) Baba, M., N. Kanzaki, H. Miyake, X. Wang, K. Takashima, K. Teshima, M. Shiraishi, and Y. Iizawa. Presented at the 12th Conference on Retroviruses and Oppotunistic Infections. 2005."},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.16.8654-8662.2004"},{"key":"52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2234683100"}],"container-title":["Uirusu"],"original-title":[],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T03:38:09Z","timestamp":1626752289000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/jsv\/55\/1\/55_1_85\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.2222\/jsv.55.85","relation":{},"ISSN":["0042-6857"],"issn-type":[{"value":"0042-6857","type":"print"}],"subject":[],"published":{"date-parts":[[2005]]}}}